LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

First Diagnostic Antibody Tests Now Available for Zika Virus

By LabMedica International staff writers
Posted on 15 Feb 2016
Print article
Image: Indirect immunofluorescence (IIF) assay of cells infected with Zika virus using a in the first available serological tests package for specific diagnosis of and screening for Zika virus infection (Photo courtesy of EUROIMMUN).
Image: Indirect immunofluorescence (IIF) assay of cells infected with Zika virus using a in the first available serological tests package for specific diagnosis of and screening for Zika virus infection (Photo courtesy of EUROIMMUN).
The complete package of two serological assays for Zika virus (ZIKV) infection enables diagnosis as well as population screening and surveillance by rapid, sensitive, and specific detection of antibodies (IgM, IgG) against the virus in blood of infected patients.

The test package, developed by EUROIMMUN AG (Luebeck, Germany), contains ELISA and indirect immunofluorescence (IIF) diagnostic tests and will shortly be used in studies at Fiocruz (Fundacao Oswaldo Cruz), an institute linked to the Brazilian health ministry.

“We have reacted immediately to the acute demand and developed ELISA and IIF tests which we have evaluated in cooperation with the Bernhard-Nocht Institute in Hamburg. The tests are suitable for the fast screening of large sample numbers and therefore enable monitoring of the virus spread,” said Katja Steinhagen, head of ELISA Infectious Serology, EUROIMMUN.

Serological tests are an important diagnostic supplement to direct detection, which is only effective during the viremic phase. Serological analyses are, moreover, crucial for epidemiological studies and monitoring. The EUROIMMUN test can detect both acute infections (in most cases from day-5 after onset of symptoms) and past infections. Test systems for direct detection of the virus (e.g., PCR) are useful only up to 5 days after onset of symptoms—after this, the virus itself is no longer detectable.

Zika fever is difficult to distinguish clinically from dengue fever and chikungunya fever, which manifest with similar symptoms and are endemic in much the same geographic regions. Thus, laboratory tests are crucial for effective differential diagnostics.

“Our ELISAs are based on very specific, recombinant antigens which are produced in our own research laboratories. Positive results are a clear indicator of a Zika virus infection” said Katja Steinhagen, “And our special immunofluorescence mosaics help laboratory physicians to investigate patient samples for other viral fever diseases in parallel. This is important for differential diagnosis, since in Latin America there are also dengue and chikungunya viruses, which cause similar symptoms and are transmitted by the same species of mosquitoes as the Zika virus. We hope our test systems can help to clarify as soon as possible whether there is a link between the cases of microcephaly and Zika infections.”

EUROIMMUN’S Anti-Zika Virus ELISA (IgM or IgG) tests provide automated detection using microplates coated with a recombinant protein from ZIKV. The highly specific antigen avoids cross-reactivity with other flaviviruses.

EUROIMMUN’S Anti-Zika Virus IIFT (IgM or IgG) utilize ZIKV-infected cells as the antigenic substrate. Positive and negative results are easily evaluated by microscopy. With the “Arboviral Fever Mosaic 2, the ZIKV substrate is incubated in parallel with substrates for Chikungunya virus and Dengue virus serotypes 1 to 4. This BIOCHIP combination enables secure interpretation of test results and differential diagnostic delimitation of ZIKV, Dengue virus, and Chikungunya virus infections.

Related Links:

EuroImmun 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Systemic Autoimmune Testing Assay
BioPlex 2200 ANA Screen with MDSS

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Pathology

view channel
Image: The new AI tool can help beat brain tumors (Photo courtesy of Crytal Light/Shutterstock)

New AI Tool Classifies Brain Tumors More Quickly and Accurately

Precision in diagnosing and categorizing tumors is essential for delivering effective treatment to patients. Currently, the gold standard for identifying various types of brain tumors involves DNA methylation-based... Read more